Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : XOMA. Bull or Bear? -- Ignore unavailable to you. Want to Upgrade?

To: aknahow who wrote (11358)	8/18/1999 12:18:00 AM
From: Tharos	Read Replies (3) \| Respond to of 17367

Maybe they can't tell us and maybe again they can. Consider the PIII release I am going to post later in this note, but first, the info I got was Ellen was -- manipulated, moved, crafted, duped (make you pick) -- by a crafty and clever reporter willing to take anyting she said out of context. What I read suggests she was not/may not have been prepared for that kind of a person. A agree blame is not the correct choice of words, and even Nancy Reagan was duped by a malicious reporter (can't think of the bum's name but know he used to wear a red tie during the Reagan administration). So what I was trying to get across was give her a chance to learn from the manipulation, but next time she should be more prepared for the type of people that seem to be able to get press passes. Anyway, Xoma can't tell us what the results are? Hmmmmm.... biz.yahoo.com QLT and CIBA Vision announce regulatory submission seeking approval of Visudyne therapy for wet AMD in the United States The submission is based on 12-month data from two 24-month randomized, double-masked, placebo-controlled Phase III trials known as the TAP (Treatment of AMD with Photodynamic therapy) Investigation. The trials are taking place at 22 centers in North America and Europe and have enrolled a total of 609 patients. At the 12-month follow-up visit, among the 243 patients in the trial with predominantly classic lesions, those treated with Visudyne therapy exhibited a large treatment benefit. Specifically, based on an intent-to-treat analysis, vision was stable (defined as a loss of less than three lines of vision on a standard eye chart) or improved in 67% of these patients treated with Visudyne therapy compared to 39% of patients administered placebo. Accordingly, patients treated with Visudyne therapy were 72% more likely to retain their vision compared to the placebo group. These results were found to be statistically significant in this population for each of the two studies, as well as for the combined data (p is less than 0.001).